| Website | aldagen.com |
| Category | BioTech |
| Phone | 919-484-2571 |
| Employees | |
| Description | Proprietary regenerative cell therapies |
| Series D, 4/08 InterSouth Partners Harbert Venture Partners The Aurora Funds Tullis Health Investors | $18.4M |
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD–151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
